Abstract |
We evaluated the treatment of varicella- zoster infection with BV-araU in immuno-compromised patients with haematological malignancies in a randomized controlled study. Comparison was made between doses of 150 and 30 mg/day. For ethical reasons there was no placebo group. The percentage of patients given a 'very effective' rating by both attending physicians and the Evaluation Committee was significantly higher in the 150 mg/day group (56.0%) compared to the 30 mg/day group (15.0%). There was no significant difference in efficacy rate ('very effective' plus 'effective') between the two groups. The incidence of side effects was low (7.8%), all were mild and disappeared on stopping treatment. These results suggest that BV-araU is clinically useful, especially at a dose of 150 mg/day in immunocompromised patients. Further comparative studies between BV-araU and acyclovir or vidarabine are indicated.
|
Authors | A Hiraoka, T Masaoka, K Nagai, A Horiuchi, A Kanamaru, M Niimura, T Hamada, M Takahashi |
Journal | The Journal of antimicrobial chemotherapy
(J Antimicrob Chemother)
Vol. 27
Issue 3
Pg. 361-7
(Mar 1991)
ISSN: 0305-7453 [Print] England |
PMID | 1645332
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Antiviral Agents
- Arabinofuranosyluracil
- sorivudine
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antiviral Agents
(therapeutic use)
- Arabinofuranosyluracil
(adverse effects, analogs & derivatives, therapeutic use)
- Chickenpox
(diagnosis, drug therapy)
- Child
- Hematologic Diseases
(complications)
- Herpesvirus 3, Human
- Humans
- Immune Tolerance
- Middle Aged
- Remission Induction
|